Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population Pharmacokinetics of Trastuzumab Rezetecan in Patients With HER2-Expressing or Mutated Advanced Solid Tumors.

CPT: pharmacometrics & systems pharmacology - 1 May 2026

Gao Xuehu, Zhao Kaijing, Zhao Yanyong, Zhang Yanyan, Zhao Jun, Zhao Chen, Djebli Nassim

Abstract excerpt

Trastuzumab Rezetecan (SHR-A1811) is an antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2). It features a novel enzyme-cleavable linker and delivers the topoisomerase I inhibitor payload, rezetecan, with a drug-to-antibody ratio of approximately 6.0. Its population pharmacokinetics (PopPK) were characterized using a nonlinear mixed-effects model based on data from 645...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Camptothecin

Share to Clinical Trials, Phase I as Topic

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Immunoconjugates

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 42108732
DOI: 10.1002/psp4.70259
PMCID: PMC13274680

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population Pharmacokinetics of Trastuzumab Rezetecan in Patients With HER2-Expressing or Mutated Advanced Solid Tumors.PMID 42108732Read ↗

Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity Read ↗

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.Semantic proximity Read ↗

Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)Semantic proximity Read ↗

Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trialSemantic proximity Read ↗

SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study.Semantic proximity Read ↗

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.Semantic proximity Read ↗

Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.Semantic proximity Read ↗

Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.Semantic proximity Read ↗

Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC.Semantic proximity Read ↗

Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.Semantic proximity Read ↗

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.Semantic proximity Read ↗

Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.